This is a randomized, placebo-controlled, crossover human laboratory study investigating the dose-dependent safety and acute effects of Cannabidiol (CBD) on measures of pain and opioid craving in outpatients with opioid use disorder (OUD) receiving medication-assisted treatment with methadone or buprenorphine. With a duration of approximately 4 weeks, participants will come to the testing site for a total of five times: one initial screening session, and four experimental sessions where study medication, CBD, will be administered, separated by at least 72 hours to limit carryover effects.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Safety and tolerability of CBD measured by the Systematic Assessment for Treatment Emergent Effects (SAFTEE)
Timeframe: Baseline (30 minutes before the administration of CBD) and +240 minutes after the administration of CBD
Abuse potential of CBD measured by the Drug Effects Questionnaire (DEQ)
Timeframe: Baseline (30 minutes before the administration of CBD), and every 30 minutes after the administration of CBD (up to +240 minutes)
Cognitive effects of CBD measured by the Hopkins Verbal Learning Test (HVLT)
Timeframe: +210 minutes after the administration of CBD
Cognitive/psychomotor effects of CBD measured by the Continuous Performance Test (CPT)
Timeframe: +210 minutes after the administration of CBD